1. (Amended) An ApoA-I agonist compound comprising:

(i) an 18 to 22-residue D-enantiomeric peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I):

Z_1-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-Z_2

X_1 is D-Ala (a), Gly (G), D-Asn (n), D-Gln (q) or D-Pro (p);

X_2 is a D-enantiomeric aliphatic residue;

X_3 is D-Leu (l);

X_4 is a D-enantiomeric acidic residue;

X_5 is D-Leu (l) or D-Phe (f);

X_6 is D-Leu (l) or D-Phe (f);

X_7 is a D-enantiomeric basic residue;

X_8 is a D-enantiomeric acidic residue;

X_9 is D-Leu (l) or D-Trp (w);

X_{10} is D-Leu (l) or D-Trp (w);

X_{11} is a D-enantiomeric acidic residue or D-Asn (n);

X_{12} is a D-enantiomeric acidic residue;

X_{13} is D-Leu (l), D-Trp (w) or D-Phe (f);

X_{14} is a D-enantiomeric basic residue or D-Leu (l);

X_{15} is D-Gln (q) or D-Asn (n);

X_{16} is a D-enantiomeric basic residue;

X_{17} is D-Leu (l);

X_{18} is a D-enantiomeric basic residue;

Z_1 is R_2N- or RC(O)NR-;

Z_2 is -C(O)NRR, -C(O)OR or -C(O)OH or a salt thereof;

each R is independently -H, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_5-C_{20}) aryl, (C_6-C_{26}) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a

1 to 7-residue peptide or peptide analogue in which one or more bonds between residues 1 through 7 are independently a substituted amide, an isostere of an amide or an amide mimetic; and

each " - " between residues X_1 through X_{18} independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or

(ii) a 14 to 20-deleted D-enantiomeric peptide or peptide analogue according to formula (I) in which at least one and up to eight of residues X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9, X_{10}, X_{11}, X_{12}, X_{13}, X_{14}, X_{15}, X_{16}, X_{17} and X_{18} are optionally deleted; or

(iii) an 18 to 22-altered D-enantiomeric peptide or peptide analogue according to formula (I) in which at least one of residues X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 , X_8 , X_9 , X_{10} , X_{11} , X_{12} , X_{13} , X_{14} , X_{15} , X_{16} , X_{17} or X_{18} is conservatively substituted with another D-enantiomeric residue.

3. (Amended) The ApoA-I agonist compound of Claim 1 which is the altered D-enantiomeric peptide or peptide analogue according to formula (I).

4. (Amended) The ApoA-I agonist compound of Claim 3 in which the D-enantiomeric hydrophobic residues are fixed according to formula (I) and at least one non-fixed residue is conservatively substituted with another D-enantiomeric residue.

5. (Amended) The ApoA-I agonist compound of Claim 4 in which:

X_1 is D-Pro (p), Gly (G), D-Asn (n) or D-Ala (a);

X_2 is D-Ala (a), D-Leu (l) or D-Val (v);

X_3 is D-Leu (l);

X_5 is D-Leu (l) or D-Phe (f);

X_6 is D-Leu (l) or D-Phe (f);

X_9 is D-Leu (l) or D-Trp (w);

X_{10} is D-Leu (l) or D-Trp (w);

X_{13} is D-Leu (l), D-Trp (w) or D-Phe (f);

X_{17} is D-Leu (l); and

at least one of X_4, X_7, X_8, X_{11}, X_{12}, X_{14}, X_{15}, X_{16} and X_{18} is conservatively substituted with another D-enantiomeric residue.

6. (Amended) The ApoA-I agonist compound of Claim 3 in which the D-enantiomeric hydrophilic residues are fixed according to formula (I) and at least one non-fixed residue is conservatively substituted with another D-enantiomeric residue.

7. (Amended) The ApoA-I agonist compound of Claim 6 in which:

X_4 is D-Asp (d) or D-Glu (e);

X_7 is D-Arg (r), D-Lys (k) or D-Orn;

X_8 is D-Asp (d) or D-Glu (e);

X_{11} is D-Asn (n) or D-Glu (e);

X_{12} is D-Glu (e);

X_{14} is D-Lys (k), D-Arg (r) or D-Orn;

X_{15} is D-Gln (q) or D-Asn (n);

X_{16} is D-Lys (k), D-Arg (r) or D-Orn;

X_{18} is D-Asn (n) or D-Gln (q); and

at least one of X_1, X_2, X_3, X_5, X_6, X_9, X_{10}, X_{13} and X_{17} is conservatively substituted with another D-enantiomeric residue.

8. (Amended) The ApoA-I agonist compound of Claim 6 in which X_3 is D-Leu (l), X_6 is Phe (f), X_9 is D-Leu (l) or D-Trp (w), X_{10} is D-Leu (l) or D-Trp (w) and at least one of X_1, X_2, X_5, X_{13} and X_{17} is conservatively substituted with another D-enantiomeric residue.

9. (Amended) The ApoA-I agonist compound of Claim 5 or 7 in which the substituting D-enantiomeric residue is classified within the same sub-category as the substituted D-enantiomeric residue.

10. (Amended) The ApoA-I agonist compound of Claim 1 which is the deleted D-enantiomeric peptide or peptide analogue according to formula (I).

11. (Amended) The ApoA-I agonist compound of Claim 10 in which one or two helical turns of the D-enantiomeric peptide or peptide analogue is optionally deleted.

12. (Amended) The ApoA-I agonist compound of Claim 1 which is an 18-residue D-enantiomeric peptide or peptide analogue according to formula (I).

13. (Amended) The ApoA-I agonist compound of Claim 12 in which
the "-" between residues designates -C(O)NH-;
Z_1 is H_2N-; and
Z_2 is -C(O)OH or a salt thereof.

14. (Amended) The ApoA-I agonist compound of Claim 13, in which;
X_1 is D-Ala (a), Gly (G), D-Asn (n) or D-Pro (p);
X_2 is D-Ala (a), D-Val (v), or D-Leu (l);
X_3 is D-Leu (l);
X_4 is D-Asp (d) or D- Glu (e);
X_5 is D-Leu (l) or D-Phe (f);
X_6 is D-Leu (l) or D-Phe (f);
X_7 is D-Arg (r), D-Lys (d) or D-Orn;
X_8 is D-Asp (d) or D-Glu (e);
X_9 is D-Leu (l) or D-Trp (w);
X_{10} is D-Leu (l) or D-Trp (w);

X_{11} is D-Glu (e) or D-Asn (n);

X_{12} is D-Glu (e);

X_{13} D-Leu (l), D-Trp (w) or D-Phe (f);

X_{14} is D-Arg (r), D-Lys (k) or D-Orn;

X_{15} is D-Gln (q) or D-Asn (n);

X_{16} is D-Arg (r), D-Lys (k) or D-Orn;

X_{17} is D-Leu (l); and

X_{18} is D-Arg (r), D-Lys (d) or D-Orn.

16. (Amended) A multimeric ApoA-I agonist compound which comprises formula (II):

(II) $HH\{LL_m\text{-}HH\}_nLL_m\text{-}HH$

or a pharmaceutically acceptable salt thereof, wherein:

each m is independently an integer from 0 to 1;

n is an integer from 0 to 10;

each "HH" is independently a peptide or peptide analogue according to Claim 1;

each "LL" is independently a bifunctional linker; and

each " - " independently designates a covalent linkage.

17. (Amended) A multimeric ApoA-I agonist compound which comprises formula (III):

(III) $X\text{-}N_{ya}\text{-}X_{(ya-1)}(\text{-}N_{yb}\text{-}X_{(yb-1)})_p$

or a pharmaceutically acceptable salt thereof, wherein:

each X is independently $HH(\text{-}LL_m\text{—}HH\text{-})_nLL_m\text{—}HH$;

each HH is independently a peptide or peptide analogue according to Claim 1;

each LL is independently a bifunctional linker;

each m is independently an integer from 0 to 1;

each n is independently an integer from 0 to 8;

N_{ya} and N_{yb} are each independently a multifunctional linking moiety where y_a and y_b represent the number of functional groups on N_{ya} and N_{yb}, respectively;

each y_a or y_b is independently an integer from 3 to 8;

p is an integer from 0 to 7; and

each "—" independently designates a covalent bond.

18. (Amended) A multimeric ApoA-I agonist compound which comprises formula (IV) or (V):



(IV)

-OR-



(V)

or a pharmaceutically acceptable salt thereof, wherein:

each X is independently HH-(-LL_m—HH-)-$_n$$LL_m$—HH;

each HH is independently a peptide or peptide analogue according to Claim 1;

each LL is independently a bifunctional linker;

each n is independently an integer from 0 to 1;

each m is independently an integer from 0 to 8;

R_1 is -OR or -NRR; and

each R is independently -H, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_5-C_{20}) aryl, (C_6-C_{26}) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl.

19. (Amended) The multimeric ApoA-I agonist compound of Claim 16, 17 or 18 in which the bifunctional linker is cleavable.

20. (Amended) The multimeric ApoA-I agonist compound of Claim 16, 17 or 18 in which n is 0.

21. (Amended) The multimeric ApoA-I agonist compound of Claim 20 in which m is 0.

22. (Amended) The multimeric ApoA-I agonist compound of Claim 16, 17 or 18 in which each HH is independently a peptide or peptide analogue according to Claim 3.

23. (Amended) The multimeric ApoA-I agonist compound of Claim 16, 17 or 18 in which each HH is independently a peptide or peptide analogue according to Claim 10.

25. (Amended) An ApoA-I agonist-lipid complex comprising an ApoA-I agonist and a lipid, wherein the ApoA-I agonist is a peptide or peptide analogue according to Claim 1, a multimeric ApoA-I agonist compound according to Claim 16, a multimeric ApoA-I agonist compound according to Claim 17, or a multimeric ApoA-I agonist compound according to Claim 18.

33. (Amended) A pharmaceutical composition comprising an ApoA-I agonist and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist is in the

form of an ApoA-I agonist-lipid complex, said complex comprising an ApoA-I agonist compound and a lipid.

39. (Amended) The pharmaceutical composition of Claim 33, which is in the form of a lyophilized powder.